Schering AG

From Wikipedia, the free encyclopedia
For the surname, see Schering (surname). For the American pharmaceutical company, see Schering-Plough.
Schering AG
IndustryPharmaceutical
PredecessorChemische Werke Essener Steinkohle Edit this on Wikidata
Founded1851
Defunct2006
FateMerged
SuccessorBayer Schering Pharma AG
Bayer HealthCare Pharmaceuticals
HeadquartersBerlin-Wedding, Germany
Key people
Hubertus Erlen, last CEO
ProductsGynaecology & Andrology
Special therapeutics
Diagnostical devices & Nuclear medicine
Oncology
Number of employees
26,000 (2004)
Websitehttp://pharma.bayer.com
Headquarters of Schering AG, now Bayer HealthCare Pharmaceuticals, in Berlin
Office building for pharmacological science in Berlin

Schering AG was a research-centered German multinational pharmaceutical company headquartered in Wedding, Berlin, which operated as an independent company from 1851 to 2006. In 2006, it was bought by Bayer AG and merged to form the Bayer subsidiary Bayer Schering Pharma AG, which was renamed Bayer HealthCare Pharmaceuticals in 2011. Schering was listed on the Frankfurt Stock Exchange and had 26,000 employees as of 2004.

The American pharmaceutical company Schering-Plough, formerly the Schering Corporation, was originally the US subsidiary of Schering AG, and merged with Merck & Co. in 2009.

History[]

In 1851, Ernst Christian Friedrich Schering opened the Grüne Apotheke (Green Pharmacy) in Berlin's Chausseestraße, and in 1871 converted into the name Chemische Fabrik auf Actien (formerly E. Schering). This date is the company's date of incorporation.

The company grew strongly in the following years. In 1913, the company employed 935 workers, 112 master craftsman and 180 office employees. In addition to the Berlin site, two factories were also located in Russia (Moscow and Wydriza) with over 1,000 workers and a plant in Great Britain. Turnover at the time was about 10 million German gold mark, created with the production of photochemicals and pharmaceuticals. Important products produced were salicylic acid, the antigout preparation atophan, various sleeping and disinfecting agents.

At the beginning of the 1920s, Schering took over the wash and colouring company  [de] located in the Berlin district Köpenick. In 1922, the management acquired the majority of shares in the chemical factory Chemischen Fabrik auf Actien (formerly E. Schering) from the Upper Silesian  [de].

In 1937, the companies Kokswerke und Chemische Fabriken AG and the Chemischen Fabrik auf Actien amalgamated with the sister company Schering-Kahlbaum AG and, on the same day, renamed on account of the internationally respected name Schering to Schering Aktiengesellschaft. The pharmaceutical business thus became part of a mining and chemical group, which also produced radiographic products and pesticides.

Schering was the manufacturer of Primodos.

Nazi medical experiments[]

In May 1999, survivors of Nazi medical experiment filed lawsuits against Bayer AG, Hoechst AG and Schering AG.[1][2]

In 2003, Simon Rozenkier filed a lawsuit against Schering and Bayer concerning the horrific medical "experiments" the companies participated in during the Nazi era.[3] [4] "If there was ever an example of why I titled the book about my Holocaust restitution negotiations in the Clinton administration “Imperfect Justice,” Stuart Eisenstadt wrote, "it is the case of Simon Rozenkier."[5] The lawsuit conflicted with a previous agreement under which $25 million had been set aside for victims of medical experiments, such as Rosenkier. Writing in Forward, lawyer Stuart Eizenstat wrote: "During the allocation process it became painfully evident that we simply did not have enough money to achieve anything like full justice for all of the victims".[6]

Bayer takeover 2006[]

In March 2006, Merck KGaA announced a €14.6bn bid for Schering, which by 2006 had annual gross revenue of around €5 billion[7] and employed about 26,000 people in 140 subsidiaries worldwide.[8] Bayer responded with a white knight bid and in July acquired the majority of shares of Schering for €14.6bn,[9] and in 2007, Bayer took over Schering AG and formed Bayer Schering Pharma. The acquisition of Schering was the largest take-over in Bayer's history,[8]: 49–52 [10] and as of 2015 this was one of the ten biggest pharma mergers of all time.[11]

At the time of the merger, the company employed more than 26,000 people in 140 subsidiaries worldwide. Schering's annual gross revenue was nearly €5 billion (2003).

Schering AG focused on the business areas of gynaecology, andrology, multiple sclerosis, oncology, and contrast agents. Schering's best-known products are probably its brands of combined oral contraceptive pills. Other key products included the interferon-beta brand Betaferon (Betaseron in North America) and the paramagnetic contrast agent Magnevist.

The largest German manufacturing facility was located in Bergkamen.

References[]

  1. ^ "WWII Survivors Sue German Drug Cos". AP NEWS. Retrieved 2021-03-26.
  2. ^ Staunton, Denis. "Bayer accused of involvement in Nazi medical experiments on Jews". The Irish Times. Retrieved 2021-03-26.
  3. ^ Greenhouse, Steven (2003-11-19). "Capping the Cost of Atrocity; Survivor of Nazi Experiments Says $8,000 Isn't Enough". The New York Times. ISSN 0362-4331. Archived from the original on 2010-11-15. Retrieved 2021-03-26. This year, Mr. Rozenkier filed a lawsuit accusing two German pharmaceutical giants, Bayer and Schering, of providing experts and drugs to Dr. Mengele and other Nazi doctors for sterilizations. What they did to me is beyond right and wrong, said Mr. Rozenkier, who lost his parents and four siblings in the Holocaust. They should be punished. His lawsuit, in Federal District Court in Newark, has created a legal and diplomatic tempest because the German government and German companies insist that there is no place for such litigation now.
  4. ^ "Rozenkier v. AG Schering, 196 F. App'x 93 (2006) Aug. 2, 2006 · United States Court of Appeals for the Third Circuit · No. 04-3934 196 F. App'x 93". cite.case.law. Retrieved 2021-03-26. Notwithstanding his Foundation application, Rozenkier filed suit in the Eastern District of New York against Schering AG and Bayer AG (the “Appellees”) on March 25, 2003, alleging that the Appellees had cooperated with the Nazi regime in causing his sterilization, and claiming damages under a number of tort theories, including negligence, infliction of emotional distress, assault and battery, conspiracy, fraud, and breach of the manufacturer’s duty to warn, as well as violations of international law.
  5. ^ EizenstatDecember 5, Stuart; 2003. "Imperfect Justice, or None at All: 'Legal Peace' on Holocaust Claims". The Forward. Retrieved 2021-03-26. If there was ever an example of why I titled the book about my Holocaust restitution negotiations in the Clinton administration “Imperfect Justice,” it is the case of Simon Rozenkier. Every fiber of our beings screams out for justice for Rozenkier, a slave laborer and survivor of the infamous death march to Buchenwald who was sterilized by Dr. Mengele’s diabolical medical experiments. But how to best provide that justice some 60 years later?CS1 maint: numeric names: authors list (link)
  6. ^ Eizenstat, Stuart (2003-12-05). "Imperfect Justice, or None at All: 'Legal Peace' on Holocaust Claims". Forward. The Forward Association. Retrieved 2021-09-10.
  7. ^ Schering AG press release. Feb 20, 2006 2005 a Record Year for Schering AG
  8. ^ a b B Rajesh Kumar. Mega Mergers and Acquisitions: Case Studies from Key Industries. Springer, 2012 ISBN 9781137005908
  9. ^ Marie-Eve Laforte for First Word Pharma. July 12th, 2006 Bayer completes acquisition of Schering AG
  10. ^ Griffiths, Katherine (25 June 2006). "Bayer acquires Schering in €17bn deal". The Daily Telegraph.
  11. ^ Staff Pharmaceutical Technology. April 13, 2015 Healthy appetite - the ten biggest pharmaceutical takeovers

External links[]

Coordinates: 52°32′21″N 13°22′02″E / 52.53917°N 13.36722°E / 52.53917; 13.36722

Retrieved from ""